Medicare Enrolled
Dr. Preethi John, MD
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. John from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. John?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. John
Dr. Preethi John is a medical oncology specialist in Dallas, TX, with 13 years of NPI registration. Based on federal Medicare data, Dr. John performed 49,048 Medicare services across 2,406 unique beneficiaries.
Between the years covered by Open Payments, Dr. John received a total of $5,416 from 27 pharmaceutical and/or device companies across 155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. John is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 21% volume in TX
$5,416 industry payments
Medicare Practice Summary
Medicare Utilization ↗49,048
Medicare services
Top 21% in TX for medical oncology
2,406
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,773 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 12,200 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,050 | $0 | $5 |
| Nivolumab injection (Opdivo) | 5,820 | $24 | $76 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
5,527 | $0 | $3 |
| Paclitaxel chemotherapy injection | 5,496 | $0 | $8 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,617 | $0 | $1 |
| Lanreotide injection, 1 mg A 1 mg injection of lanreotide medication administered into the body. |
1,560 | $44 | $227 |
| Anti-nausea injection (Aloxi/palonosetron) | 930 | $1 | $114 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
730 | $34 | $235 |
| Injection, granisetron hydrochloride, 100 mcg | 570 | $0 | $24 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
412 | $10 | $64 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
410 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
403 | $8 | $36 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
307 | $23 | $157 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
307 | $85 | $368 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
260 | $104 | $707 |
| Injection, leucovorin calcium, per 50 mg | 253 | $3 | $25 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
216 | $12 | $108 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
197 | $2 | $13 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
192 | $85 | $1,348 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
157 | $2 | $300 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 150 | $3 | $373 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
144 | $134 | $496 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
96 | $1 | $6 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 93 | $20 | $128 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
88 | $7 | $431 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
81 | $1 | $7 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
71 | $50 | $344 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
62 | $50 | $313 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
55 | $1 | $8 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
53 | $49 | $821 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
51 | $2 | $19 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
48 | $179 | $1,067 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
48 | $23 | $161 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
41 | $11 | $96 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
40 | $58 | $211 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 34 | $91 | $657 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
33 | $1,183 | $4,802 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
27 | $10 | $75 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
25 | $94 | $357 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
22 | $5 | $31 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
21 | $135 | $500 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
20 | $16 | $100 |
| New patient office visit, complex (60-74 min) | 20 | $165 | $709 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
19 | $16 | $94 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
18 | $19 | $99 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
17 | $81 | $500 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
16 | $44 | $289 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
14 | $44 | $686 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
14 | $15 | $96 |
| Total calcium level test A blood test that measures the total amount of calcium in your body. |
13 | $5 | $30 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.1% high complexity
92.9% medium
4.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,416
Total received (2019-2024)
Avg $903/year across 6 years
Top 46% in TX for medical oncology
27
Companies
155
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,554 (47.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,750 (32.3%)
Other
Charitable contributions, space rental, and other categories
$1,100 (20.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,835
2023
$1,135
2022
$281
2021
$48
2020
$76
2019
$41
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$1,767
Novartis Pharmaceuticals Corporation
$1,045
Daiichi Sankyo Inc.
$972
AstraZeneca Pharmaceuticals LP
$321
Stemline Therapeutics Inc.
$137
Gilead Sciences, Inc.
$123
Tactile Systems Technology Inc
$118
Merck Sharp & Dohme LLC
$108
NOVARTIS PHARMACEUTICALS CORPORATION
$100
PFIZER INC.
$91
Amgen Inc.
$80
Genentech USA, Inc.
$80
Tempus AI, Inc
$74
ABBVIE INC.
$58
Incyte Corporation
$58
Karyopharm Therapeutics Inc.
$47
Merck Sharp & Dohme Corporation
$36
Janssen Biotech, Inc.
$23
Regeneron Healthcare Solutions, Inc.
$22
SERVIER PHARMACEUTICALS LLC
$22
ADC Therapeutics America, Inc.
$22
Blueprint Medicines Corporation
$21
Jazz Pharmaceuticals Inc.
$20
Pharmacyclics LLC, An AbbVie Company
$20
Pharmacyclics LLC, an AbbVie Company
$17
Genmab U.S., Inc.
$15
Rigel Pharmaceuticals, Inc.
$15
Top 3 companies account for 69.9% of total payments
Associated products mentioned in payments ›
AYVAKIT · ENHERTU · EPKINLY · Enhertu · Epkinly · Flexitouch Plus · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · Itovebi · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · LIBTAYO · MONJUVI · Neulasta · Nplate · Orserdu · PIQRAY · Phesgo · Rezlidhia · TUKYSA · Trodelvy · VERZENIO · VYXEOS · XGEVA · XPOVIO · XT CDX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (47%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $11 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. John is a mixed practice specialist, with above-average Medicare volume (top 21% in TX), with mixed engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. John experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. John performed 12,200 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. John receive payments from pharmaceutical companies?
Yes. Dr. John received a total of $5,416 from 27 companies across 155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. John's costs compare to other medical oncologists in Dallas?
Dr. John's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. John) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology